Olympus is the largest player in the U.S. duodenoscope market, and most contaminated-scope litigation in the United States runs through Olympus models. But it is not the only manufacturer whose duodenoscopes have been recalled for contamination-related design problems. Pentax and Fujifilm — the other two major manufacturers — have run their own recalls and received their own FDA warning letters. Understanding the broader industry record helps put the Olympus story in context, and matters for patients who may have had a procedure with a non-Olympus scope.
Three Manufacturers, One Family of Design Problems
All three major duodenoscope manufacturers use a similar physical design: a long flexible tube ending in an "elevator" channel at the distal tip that can deflect a guide wire or catheter into the bile or pancreatic duct. That elevator channel is what makes ERCP possible — and it is also what makes the scope hard to clean. Biological material from one patient can become trapped in the channel and transmitted to the next.
The infection-transmission problem documented at Virginia Mason, UCLA, Cedars-Sinai, Hartford Hospital, and other hospitals is therefore not specific to one brand. It is a feature of the closed-elevator-channel design itself. The reason the Olympus litigation has been largest is not because Olympus scopes are uniquely flawed; it is because Olympus has the largest U.S. market share, the longest documented record of regulatory non-compliance, and the most publicly disclosed outbreak history.
Pentax ED-3490TK
In January 2017 the FDA issued an updated Safety Communication on the Pentax ED-3490TK duodenoscope, warning that cracks and gaps in the adhesive sealing the distal cap could allow microbial and fluid seepage into hard-to-clean crevices. Pentax issued a voluntary recall to correct the design.
On February 7, 2018, the FDA cleared a new ED-3490TK design with a redesigned elevator channel sealing mechanism intended to prevent the seepage problem. Pentax issued updated labeling and reprocessing instructions alongside the design correction.
Fujifilm ED-530XT
On July 21, 2017, Fujifilm issued an Urgent Medical Device Correction and Removal notification covering all ED-530XT duodenoscopes — a full-fleet recall, not a partial one. The corrective action included replacement of the forceps elevator mechanism (including the O-ring seal), replacement of the distal end cap, and new operation manuals.
The Fujifilm recall was contemporaneous with the Pentax action and tracked the same regulatory concern: that the elevator channel and its associated seals were hard to clean and could harbor bacteria between patients.
August 2015: FDA Warning Letters to All Three Manufacturers
In August 2015 the FDA posted warning letters to all three duodenoscope manufacturers — Olympus, Pentax, and Fujifilm. The letters alleged that each company had failed to timely report device-linked infections, injuries, or deaths to the FDA. This was a coordinated regulatory action, and it framed the industry — not any single manufacturer — as the focus of federal concern.
The warning letters became the basis for the Department of Justice's later criminal investigation, which eventually produced the December 2018 Olympus deferred prosecution agreement. Pentax and Fujifilm did not face comparable DOJ resolutions, but the underlying FDA findings about delayed adverse-event reporting applied to all three.
The U.S. Senate HELP Committee Report (2016)
The January 2016 U.S. Senate Health, Education, Labor and Pensions Committee report — "Preventable Tragedies: Superbugs and How Ineffective Monitoring of Medical Device Safety Fails Patients" — treated the duodenoscope contamination problem as an industry-wide issue rather than a single-manufacturer issue. The report documented 25 outbreak incidents affecting approximately 250 patients worldwide between 2012 and spring 2015, and it implicated all three major manufacturers in different degrees.
Olympus's role in the Senate findings was the largest by far — both because of market share and because of the specific evidence (in Olympus's own internal documents) that the company knew its TJF-Q180V scope was hard to clean and chose not to alert U.S. customers for nearly two years. But Pentax and Fujifilm were part of the same regulatory picture.
What This Means for Patients
If you had any duodenoscope procedure — ERCP, certain advanced upper endoscopies — and later developed a bacterial bloodstream infection, the contaminated-scope question is worth asking regardless of which manufacturer's scope was used. The first step is the same as for Olympus cases: pull the procedure record and identify the device.
That said, the current litigation landscape is heavily Olympus-focused. The 2025 FDA import alert covers 58 Olympus models. The 2026 wave of FDA recalls (OER-Pro reprocessor, high flow insufflation units, endoscope needles) is Olympus-specific. The Quebec class action filed by Siskinds LLP in April 2026 is also Olympus-focused. Pentax and Fujifilm have largely stayed out of the post-2024 news cycle, even though the underlying industry-wide design issue remains the same.
For a patient with a non-Olympus scope procedure and an unexplained post-procedure infection, the case analysis is similar to an Olympus case but typically more fact-intensive because the regulatory record is thinner. The free case review evaluates it on the merits.
If You Think You May Have Been Affected
We represent patients nationwide, regardless of where the procedure happened or which manufacturer's scope was involved. A free case review takes about 15 minutes by phone, and we evaluate the medical timeline, the device involved, and your state's filing deadlines before you decide whether to move forward.
- Read the latest litigation status: June 2026 Olympus Lawsuit Update.
- Review the documented hospital outbreak history: Documented U.S. Hospital Outbreaks.
- Understand the symptom timeline that often hides the connection: When Scope Infection Symptoms Appear.
- See if your case profile fits: 3-part qualification test.
Free case review. No Fees Unless We Recover Money for You.
Sources
- U.S. Food & Drug Administration — "FDA In Brief: FDA clears design changes to Pentax duodenoscope to improve cleaning and disinfection; voluntary recall of duodenoscope model to implement correction." fda.gov
- MassDevice — "Pentax Medical recalls ED-3490TK duodenoscopes." massdevice.com
- Imaging Technology News — "Fujifilm Issues Voluntary Recall of All ED-530XT Duodenoscopes" (July 2017). itnonline.com
- Becker's ASC Review — "FDA recalls Fujifilm ED-530XT duodenoscopes — 4 key notes." beckersasc.com
- Medscape — "Fujifilm Issues Urgent Recall of ED-530XT Duodenoscopes." medscape.com
- Drugwatch — "Pentax Duodenoscope Flaw Linked to Infection Risk" (January 2017). drugwatch.com
- U.S. Senate Committee on Health, Education, Labor and Pensions — "Preventable Tragedies: Superbugs and How Ineffective Monitoring of Medical Device Safety Fails Patients" (January 2016). help.senate.gov
- U.S. Department of Justice — "Olympus Medical Systems Corporation Pleads Guilty to Distributing Endoscopes After Failing to File FDA-Required Adverse Event Reports of Serious Infections" (December 2018). justice.gov
Think You May Have a Case?
The 3-part qualification test takes 2 minutes. If it fits your situation, a free case review is the next step. No Fees Unless We Recover Money for You.